DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Hims compounded semaglutide (compounded semaglutide (non-FDA-approved)) costs $199/month via Hims telehealth subscription, Not covered with insurance + savings card, or up to N/A (telehealth only) retail. Updated for 2026.
Same drug, different pricing channels. The spread is often $800-1000/month between cheapest and retail cash.
Hims compounded semaglutide costs $199/month flat for the starter and titration tiers (0.25mg–0.5mg). Maintenance doses (1.0mg+) run $249–$299/month. Hims subscription includes provider visit, prescription, shipping. No retail pharmacy option — compounded semaglutide is only available through telehealth platforms with 503A pharmacy partnerships.
Hims compounded semaglutide is NOT covered by insurance — compounded medications are not on insurance formularies. There is no path to insurance coverage for this product. If you have insurance that covers Wegovy or Ozempic, those are the FDA-approved alternatives.
Hims offers duration discounts: $199/month single, $165/month on 3-month plan (17% savings), $149/month on annual plan (25% savings). No manufacturer savings cards available (Hims is not a manufacturer — it's a telehealth platform compounding through 503A pharmacy partners).
Medicare does not cover compounded semaglutide. Compounded medications are excluded from Medicare Part D formularies. For Medicare members, FDA-approved Wegovy (cardiovascular indication only) or Ozempic (T2D) are the covered alternatives.
Medicaid does not cover compounded semaglutide. Same exclusion applies — compounded medications are not on Medicaid formularies. For Medicaid members in covered states, FDA-approved Wegovy or Ozempic are the covered alternatives.
$499/month — FDA-approved Wegovy, manufacturer-direct. 2.5x more expensive than compounded, but eliminates regulatory risk.
$499/month NovoCare direct or $25/month with T2D insurance — FDA-approved Ozempic. Only available for type 2 diabetes patients.
$199–$299/month range — same regulatory profile as Hims. Pricing competitive. Quality varies by 503A pharmacy partner.
Hims compounded semaglutide is $149–$299/month depending on dose and duration plan — substantially cheaper than FDA-approved Wegovy or Ozempic. The trade-off is regulatory risk: the FDA's October 2024 removal of semaglutide from the shortage list means compounders face wind-down requirements. Treat as a bridge, not a destination.
Pricing verified monthly against current manufacturer and pharmacy formularies. Coverage rules vary by plan — verify against your member portal before prescribing.